<DOC>
	<DOCNO>NCT00549068</DOCNO>
	<brief_summary>To compare subject satisfaction rating woman treat postmenopausal osteoporosis Actonel 35mg Once-a-Week 24 week , receive feedback information , 12 week treatment , base bone resorption marker result use NTx Point-Of-Care ( POC ) device , similar woman treat per regular clinical practice</brief_summary>
	<brief_title>POWER Point Care Effect Satisfaction Treatment</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<criteria>Women diagnose postmenopausal osteoporosis use community practice standard Women previously nontreated osteoporosis , OR treat osteoporosis biphosphonates ( alendronate , etidronate ) , hormone replacement therapy estrogen , estrogenrelated drug , progesterone , subcutaneous estrogen implant ) , raloxifene , fluoride , calcitonin within past 2 year discontinue prior enrolment study either due : lack effect intolerance Subjects treat Actonelr 5 mg daily , Mental condition render subject unable understand nature , scope , possible consequence study Subject unlikely comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood complete study Known/Suspected hypersensitivity component Actonelr 35 mg OnceaWeek Known/Suspected hypocalcaemia Known/Suspected severe renal impairment ( creatinine clearance &lt; 30ml/min ) Known/Suspected hyperparathyroidism Known/Suspected hyperthyroidism Known/Suspected active urinary tract infection Known high urine level calcium ( 3 4mg/ml ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>